文献速递病毒性肝炎

丙型肝炎病毒疫苗研发中的受控人类感染模型:试验设计考量

Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.
PubMed 文献 · Clin Infect Dis · 2023-01-01

本文讨论了用于加速丙型肝炎病毒(HCV)疫苗研发的受控人类感染模型(CHIM)的试验设计。设计包括初始哨兵队列以确定病毒接种物的安全性和可治愈性,随后扩大队列以确定每种接种物的自发清除率。主要终点为接种后24周内HCV清除,并讨论了入组人群、监测方法、抗病毒治疗指征、样本量及安全性等考量。

要点

  • CHIM设计需先哨兵队列确认接种物安全可治愈,再扩大队列评估自发清除率。
  • 主要终点为接种后24周HCV清除,反映疫苗预防慢性感染的目标。
  • 需考虑入组人群、监测方案、抗病毒治疗指征及不同CHIM方法的样本量。

核心结论

  • HCV CHIM的试验设计需仔细考量,包括哨兵队列、自发清除率评估、主要终点及安全性等。

研究设计与样本

  • 提出一种HCV CHIM的潜在方法设计,包括初始哨兵队列和后续扩大队列。

主要发现

  • 初始哨兵队列用于确定病毒接种物的安全性和可治愈性,后续扩大队列用于确定每种接种物的自发清除率。
  • 主要终点为接种后24周时HCV清除,因为预防慢性感染是HCV疫苗候选的主要目标。

关键数值与推荐

  • 主要终点为接种后24周时HCV清除。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The design of a clinical trial for a controlled human infection model (CHIM) to accelerate hepatitis C virus (HCV) vaccine development requires careful consideration. The design of a potential approach to HCV CHIM is outlined, involving initial sentinel cohorts to establish the safety and curability of the viral inoculum followed by larger cohorts to establish the spontaneous clearance rate for each inoculum. The primary endpoint would be HCV clearance by 24 weeks post-inoculation, recognizing that the prevention of chronic infection would be the primary goal of HCV vaccine candidates. Additional considerations are discussed, including the populations to be enrolled, the required monitoring approach, indications for antiviral therapy, and the required sample size for different CHIM approaches. Finally, safety considerations for CHIM participants are discussed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Feld JJ, Bruneau J, Dore GJ, et al. Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations. Clin Infect Dis. 2023. PMID: 37579209. doi:10.1093/cid/ciad362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。